Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer - investigation of a correlation with Gleason score

NMR in Biomedicine

Volumn 26, Issue 5, 2013, Pages 600-606

  Selnæs, Kirsten M ^a,b   Gribbestad, Ingrid S ^a,b   Bertilsson, Helena ^a,b   Wright, Alan ^c   Angelsen, Anders ^b   Heerschap, Arend ^a,c   Tessem, May Britt ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

High resolution magic angle spinning; HR MAS MRS; Metabolite ratios; MRS and MRSI; Prostate cancer aggressiveness

Indexed keywords

HIGH RESOLUTION MAGIC ANGLE SPINNING; HR MAS MRS; METABOLITE CONCENTRATIONS; MRS AND MRSI; POSITIVE CORRELATIONS; PROSTATE CANCERS; RADICAL PROSTATECTOMY; SPEARMAN'S RANK CORRELATION;

BIOMOLECULES; DISEASES; METABOLISM; METABOLITES; TISSUE; UROLOGY;

TRANSPLANTS;

CHOLINE; CITRIC ACID; CREATININE; SPERMINE;

ADULT; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ACTIVITY; EX VIVO STUDY; FROZEN SECTION; GLEASON SCORE; HIGH RESOLUTION MAGIC ANGLE SPINNING MAGNETIC RESONANCE SPECTROSCOPY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; METABOLIC RATE; METABOLITE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE SLICE;

AGED; AGED, 80 AND OVER; CHOLINE; CITRIC ACID; CREATINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; SPERMINE;

EID: 84876793815     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2901     Document Type: Article

References (31)

1. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 2011; 59(1): 61-71.
2. Hoeks CM, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SW, Scheenen TW, Vos PC, Huisman H, van Oort IM, Witjes JA, Heerschap A, Futterer JJ. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261(1): 46-66.
3. Santos CF, Kurhanewicz J, Tabatabai ZL, Simko JP, Keshari KR, Gbegnon A, Santos RD, Federman S, Shinohara K, Carroll PR, Haqq CM, Swanson MG. Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR Biomed. 2010; 23(4): 391-398.
4. Bathen TF, Sitter B, Sjobakk TE, Tessem MB, Gribbestad IS. Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res. 2010; 70(17): 6692-6696.
5. Keshari KR, Tsachres H, Iman R, Delos Santos L, Tabatabai ZL, Shinohara K, Vigneron DB, Kurhanewicz J. Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment. NMR Biomed. 2011; 24(6): 691-699.
6. 1H HR-MAS spectroscopy. Magn. Reson. Med. 2006; 55(6): 1257-1264.
7. 1H HR-MAS spectroscopy of biopsy tissues. Magn. Reson. Med. 2008; 60(3): 510-516.
8. Scheenen TW, Futterer J, Weiland E, van Hecke P, Lemort M, Zechmann C, Schlemmer HP, Broome D, Villeirs G, Lu J, Barentsz J, Roell S, Heerschap A. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest. Radiol. 2011; 46(1): 25-33.
9. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imaging 2002; 16(4): 451-463.
10. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 1974; 111(1): 58-64.
11. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, Muruganandham M, Ebora L, Kattan MW, Reuter VE, Scardino PT, Koutcher JA. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234(3): 804-814.
12. Kobus T, Hambrock T, Hulsbergen-van de Kaa CA, Wright AJ, Barentsz JO, Heerschap A, Scheenen TW. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3T with an endorectal coil. Eur. Urol. 2011; 60(5): 1074-1080.
13. van Asten JJ, Cuijpers V, Hulsbergen-van de Kaa C, Soede-Huijbregts C, Witjes JA, Verhofstad A, Heerschap A. High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. MAGMA 2008; 21(6): 435-442.
14. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, Barentsz JO, Heerschap A. Three-dimensional proton MR spectroscopy of human prostate at 3T without endorectal coil: feasibility. Radiology 2007; 245(2): 507-516.
15. 1H-MR spectroscopy. J. Nucl. Med. 2010; 51(11): 1676-1683.
16. Garcia-Martin ML, Adrados M, Ortega MP, Fernandez Gonzalez I, Lopez-Larrubia P, Viano J, Garcia-Segura JM. Quantitative (1)H MR spectroscopic imaging of the prostate gland using LCModel and a dedicated basis-set: correlation with histologic findings. Magn. Reson. Med. 2011; 65(2): 329-339.
17. 1H HR-MAS for childhood brain tumours. NMR Biomed. 2009; 22(2): 213-219.
18. Opstad KS, Wright AJ, Bell BA, Griffiths JR, Howe FA. Correlations between in vivo (1)H MRS and ex vivo (1)H HRMAS metabolite measurements in adult human gliomas. J. Magn. Reson. Imaging 2010; 31(2): 289-297.
19. 1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration. NMR Biomed. 2004; 17(1): 1-9.
20. Bertilsson H, Angelsen A, Viset T, Skogseth H, Tessem MB, Halgunset J. A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy. Prostate 2011; 71(5): 461-469.
21. 1H-MR spectroscopic imaging of the human prostate at 3T. Magn. Reson. Med. 2005; 53(6): 1268-1274.
22. Scheenen TW, Klomp DW, Roll SA, Futterer JJ, Barentsz JO, Heerschap A. Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn. Reson. Med. 2004; 52(1): 80-88.
23. 1H HR MAS MR spectroscopy and chemometric analysis. J. Proteome Res. 2010; 9(7): 3664-3670.
24. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993; 30(6): 672-679.
25. 13C inverse 2D method for the analysis of the polyamines putrescine, spermidine and spermine in cell extracts and biofluids. NMR Biomed. 1998; 11(2): 47-54.
26. van der Graaf M, Heerschap A. Effect of cation binding on the proton chemical shifts and the spin-spin coupling constant of citrate. J. Magn. Reson. B 1996; 112(1): 58-62.
27. Spectral Database for Organic Compounds. Available at: http://riodb01.ibase.aist.go.jp/sdbs/ [accessed August 2007].
28. Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000; 56(5): 823-827.
29. Bewick V, Cheek L, Ball J. Statistics review 10: further nonparametric methods. Crit. Care 2004; 8(3): 196-199.
30. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Futterer JJ. ESUR prostate MR guidelines 2012. Eur. Radiol. 2012; 22(4): 746-757.
31. Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA, Scheenen T, Barentsz JO. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011; 259(2): 453-461.